Did Eli Lilly Just Say Checkmate to Novo Nordisk?

Though oncology remains the largest therapeutic area in the pharmaceutical industry, the weight management field has caught fire in the past few years. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger.Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in the weight loss space. Should investors buy the company's shares? Let's find out.In December, Eli Lilly released top-line data from a phase 3 clinical trial that pitted its weight loss medicine Zepbound with Novo Nordisk's Wegovy. These preliminary results showed that Zepbound produced an average weight loss of 20.2% versus 13.7% for Wegovy. Unlike when we compare data from separate trials, a head-to-head study provides strong evidence of which drug is more effective, and according to this one, that's Zepbound.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool